权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeted degradation of RNAs by using small molecules

使用小分子靶向降解 RNA

基本信息

批准号：
10661487
负责人：
Matthew D Disney
金额：
$ 66.16万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10661487
关键词：
Animals Antisense Oligonucleotides Apoptosis Base Sequence Benchmarking Binding Binding Proteins Biogenesis Breast Cancer Cell Breast Cancer Model Breast Cancer Patient Breast Cancer cell line Breast Epithelial Cells Cancer Center Cell Proliferation Cells Chimera organism Clinical Clustered Regularly Interspaced Short Palindromic Repeats Complementary RNA Development Disease Engineering Evaluation Genetic Transcription Goals Human In Situ In Vitro Invaded Laboratories Lead MDA MB 231 Malignant Neoplasms Medicine Methods MicroRNAs Modality Mus Mutation Neoplasm Metastasis Normal tissue morphology Oligonucleotides Oncogenic Patients Pharmaceutical Preparations Phenotype Production Proliferating Property Protac Protein Inhibition Proteins Proteome RNA RNA Binding RNA Degradation RNA Splicing Resources Ribonuclease H Ribonucleases Role Safety Site Testing Triage Tumor Suppressor Proteins Tumor Tissue Untranslated RNA Validation Xenograft Model derepression design efficacy evaluation efficacy testing improved in vivo in vivo evaluation knock-down lead optimization malignant breast neoplasm migration neoplastic cell novel therapeutic intervention nuclease programs rational design recruit relapse prevention response small molecule stem cell biomarkers targeted treatment tool transcriptome triple-negative invasive breast carcinoma tumor tumorigenesis

项目摘要

We propose a transformative approach, inspired by the mechanism of action of antisense oligonucleotides (ASOs), to deliver small molecules that selectively cleave RNA targets in cells and in animals. As a state-of-the- art modality to target RNA, ASOs bind to complementary RNAs and recruit endogenous RNase H, which then cleaves the RNA to eliminate it from the cell. As an alternative to ASOs, we have developed a class of small molecules that selectively bind to and cleave an RNA target and have shown that our new cleaving small molecules are more potent than simple binding compounds. Our approach, dubbed Ribonuclease targeting chimeras (RIBOTACs), engineers small molecules to recruit endogenous RNase L, an RNase expressed at minute levels in cells in a latent form (hence RNase L). The chimeras, comprised of RNA-binding modules and a heterocyclic RNase L-recruiting module, activate RNase L locally at the site of the desired target. We will fully develop our RIBOTAC approach to cleave RNA targets sub-stoichiometrically and catalytically with small molecules, providing a direct means to improve the potency of simple binding compounds. Collectively, we will deliver a platform to program small molecules to cleave specific, malfunctioning RNAs in cells and in animals, with superior properties as compared to ASOs. In support of these goals, we propose in Aim 1 to characterize comprehensively our lead RIBOTAC targeting miR-21 in vitro and in situ, a benchmark for lead optimization. Our new studies show that the binding compound from which this RIBOTAC is derived inhibits metastasis in an orthotopic xenograft model. Further, the RIBOTAC is 20-fold more potent than the simple binding compound in situ for inhibiting miR-21 biogenesis and breast cancer cell phenotypes. Of import, we will study and quantify the selectivity of the RIBOTAC transcriptome- and proteome-wide. In Aim 2, we will lead optimize our RIBOTAC to deliver a proof-of-concept compound with properties amenable for in vivo testing. These DMPK-driven studies will optimize all components of the RIBOTAC, from the RNA-binding modules to the linker that tethers them together to the RNase L-recruiting module. We will rigorously assess top RIBOTACs in the triple negative breast cancer (TNBC) cell line MDA- MB-231, including full assessment and quantification of selectivity transcriptome- and proteome-wide. Finally, in Aim 3, we will study optimized RIBOTACs for activity against a panel of TNBC and patient-derived (PDX) tumor cells ex vivo and in vivo. After confirming miR-21 destruction by our RIBOTACs, we will assess their effects on TNBC cell: (i) proliferation; (ii) survival; (iii) migration and invasion; and (iv) expression of EMT and breast cancer stem cell markers. RIBOTACs with the broadest activity against TNBCs will be evaluated for efficacy in vivo.

我们提出了一种变革性的方法，灵感来自反义寡核苷酸的作用机制